October 26, 2012
Teva Pharmaceutical Industries Ltd. and GlaxoSmithKline LLC were hit Thursday with another proposed class action alleging the companies manipulated a patent settlement to inflate the cost of epilepsy drug Lamictal or its generic equivalent.